Introduction
Purinergic receptors, which are widely distributed in the gastrointestinal tract, mediate signalling in enteric glia, the enteric nervous system and at the neuromuscular junction [1] [2] [3] [4] [5] . Figure 1 is a schematic showing the characterisation of purinoceptors in the gut. There are three classes of purinoceptors: seven subtypes of ligand-gated ion channels (P2XRs), eight subtypes of nucleotide-activated G protein-coupled receptors (P2YRs) and four subtypes of G protein-coupled adenosine receptors (ARs, also designated P1 receptors). Our knowledge is based primarily on animal data, although recent studies described here focus more on purinergic signalling in the human gut. Purinergic receptors are key components of, and function at all levels of enteric neural reflexes and in both intrinsic and extrinsic neural pathways. Furthermore, purinergic signalling is an important regulator in activation and trafficking of immune/inflammatory cells [6] [7] [8] . Activation of P2Rs generally boosts the immune response, while ARs tend to suppress it. Therefore, it is not surprising that there is a great deal of interest in further understanding the role of purines in pathogenic mechanisms and their therapeutic potential in gastrointestinal diseases, as reviewed [9, 10] .
Medicinal chemistry of purinergic receptors
The X-ray crystallographic structures of ARs and P2YRs are aiding the design of novel ligands by rational structure-based approaches [11] . However, most commonly used AR ligand tools were discovered by empirical approaches (Figure 2 , [3, 12 ] ). Cl-ENBA (number 3 in Figure 2 ) is a more selective A 1 AR agonist for in vivo use than 1 and 2 [13] . CGS21680 (not shown) is an A 2A AR agonist in rat, but has substantial human (h) A 3 AR affinity [14] . Potent A 2A AR agonist ATL-313 5 attenuates colitis in mice and reduces pro-inflammatory cytokines [8] . UK-432097 6 is a potent, selective A 2A AR agonist with limited oral bioavailability. Regadenoson 4 is approved as a vasodilator for stress echocardiography but is only moderately potent and not selective at the A 2A AR. Selective human A 2A AR agonist PBS-0777 7 is water-soluble and does not diffuse across biological membranes. MRS5698 11 is a more selective A 3 AR agonist than 9 and 10 [13] . Selective antagonists are available for all four ARs (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) , but their affinity is often species dependent. For example, typical heterocyclic A 3 AR agonists display only weak affinity at rodent A 3 ARs, but MRS1523 21 remains somewhat A 3 AR-selective across species [14] .
Agonist and antagonist ligands are available for most P2YRs [12 ] ,but onlyantithrombotic P2Y 12 Rantagonists(Figure3, [22] [23] [24] [25] are approved internationally for human use. Thienopyridines 9 and 10 act as prodrugs that are converted into irreversibly binding selective P2Y 12 R antagonists.
Although there are seven subtypes of P2XRs, each functional channel consists of trimers. Each heterotrimeric combination may differ in ligand pharmacology from the homotrimer, which introduces complexity in the medicinal chemistry. Examples of such heterotrimers are P2X2/ 3, P2X2/4 and P2X4/6 ( Figure 1 ). X-ray structures of the zebrafish P2X4R, human P2X3R and panda P2X7R are reported and are being utilized for the homology modeling of binding of various ligands at related P2X1R, P2X3R and P2X7R subtypes [15] [16] [17] .
P2XR antagonists are available for P2X2R and P2X2/3R (26, 27) , P2X3R (28), P2X4R (26, 27 ) and P2X7R (30-41) [12 ] . Many of the nonpolar antagonists are, in fact, allosteric. Several nonpolar P2X7R antagonists have been in clinical trials for inflammatory disease, cancer, and depression [18, 19] . Numerous pharmaceutical companies (with compound numbers) have been involved in discovery of P2X7R antagonists (e.g. Pfizer 30; Glaxo Structures of commonly used ligand probes, both agonists and antagonists, of the four AR subtypes. Ligand potencies and species dependence are reported [12 ,72] . Only one ligand shown here, in addition to adenosine and theophylline, has been approved for human use: 4 (diagnostic).
31; Astra-Zeneca 32, 33; Lundbeck 34; Axxam 35; Abbvie 36; Janssen 37, 38, 40; Actelion 39). AZD9056 32 was the first P2X7R antagonist to be tested clinically, significantly improving in rheumatoid arthritis scores [20] . AZ10606120 33 binding at the P2X7R was probed structurally [15] . Compounds 38 and 40 are PET ligands for imaging of P2X7R in the brain.
Enzymatic transformation of extracellular purines can also affect the levels of activation of purinergic receptors.
Intestinal inflammation may cause downregulation of the ectonucleotidases CD39 (E-NTPDase1) and CD73 (5 0 -nucleotidase), leading to excess nucleotide-dependent proinflammatory effects and deficiency of adenosinedependent anti-inflammatory effects in the immune and nervous systems [8] . CD39 hydrolyzes ATP and ADP to AMP, and CD73 hydrolyzes AMP to adenosine. Thus, soluble ectonucleotidases and selective A 2A AR agonists have been suggested as therapies for correcting an imbalance of purinergic signalling in inflammatory bowel disease (IBD) and gastrointestinal autoimmunity [8] .
Modulators of nucleoside transport, such as the vasodilator dipyridamole, and inhibitors of adenosine deaminase (ADA), such as the anticancer drug pentostatin, indirectly raise the level of AR activation. 
P2X7R in inflammatory bowel disease (IBD)
IBD includes two main clinical forms, ulcerative colitis (UC) and Crohn's disease (CD). Under inflammatory conditions, ATP is released. P2X7R is preferentially expressed by immune cells, particularly macrophages, which, when activated, release inflammatory cytokines, mediate inflammasome formation and enhance phagocytosis. Reviews discussing the role of P2X7R in IBD are available [21, 22] .
P2X7R is involved in colonic motor dysfunction associated with bowel inflammation. P2X7R modulates the activity of excitatory cholinergic nerves through a facilitation of inhibitory nitrergic pathways [23] .
Damage to the intestinal mucosa epithelial barrier by chemical or physical stressors induces inflammation, which results in ATP release. The ATP activates mast cells, which further promote inflammatory processes [24] . Oestrogen receptor-b activation may play a therapeutic role in IBD by down-regulating P2X3R and P2X7R [25] . P2X7R is over-expressed in IBD patients' gut mucosa. P2X7R knockout mice were protected against gut inflammation [26] . P2X7R activates the NLRP3 inflammasome in T cells, macrophages, dendritic cells, and neutrophils [27] . However, no studies have assessed the utility of P2X7R antagonists in humans with IBD except for one study in Crohn's Disease (CD) patients [28 ] .
Ulcerative colitis (UC)
Extracellular ATP mediates inflammatory responses in colitis via P2X7R signalling [29] . Colitis differentially affects P2X7R-expressing enteric neurons based on their chemical codes [30] . P2X7R activation also triggers mucosal regulatory T cell death [26] . P2X7R antagonist A438079 35 down-regulates the production of proinflammatory cytokines in colonic tissues, and attenuates murine colitis, indicating P2X7R-dependent triggering of immune responses during colitis [29] .
Extracellular ATP mediates mast cell-dependent intestinal inflammation via P2X7R. It was shown that leukocyte mono-immunoglobulin-like receptor 3-deficient colonic mast cells were pivotal in the exacerbation of experimental colitis [31] . P2X7R is predominantly located on myenteric neurons, but in colitis its neuromuscular layer expression increased, with a marked reduction of electrically induced contractions by the P2X7R agonist 2
P2X3R mediates visceral hypersensitivity during 2,4,6-trinitrobenzene sulphonic-acid-induced colitis, identifying it as a potential new target for abdominal pain syndrome treatment [32] .
Intestinal epithelial adenosine A 2B AR signalling, including activation by selective agonist Bay60-6583 9, in vivo protects during acute intestinal inflammation by regulating (Ser 157 ) phosphorylation of vasodilator stimulated phosphoprotein (VASP) at epithelial cell junctions to enhance mucosal barrier responses [33] . This pathway may be exploited as a therapeutic strategy in IBD. However, A 2B AR antagonism or gene knockout showed benefit in a mouse model of colitis [34] . Systemic administration of P2X7R antagonist A740003 protects against sepsis-induced disruption of the intestinal barrier [35, 36] .
MicroRNA-16 in human UC regulates the increase in inflammatory responses by suppressing the expression of the A 2A AR to control the activation of the NF-kB signalling pathway ( [37 ] ; Figure 4 ). MicroRNA-206 has a pro-inflammatory role in UC by downregulating A 3 AR expression and activating NF-kB signalling [35, 36] .
In a rat TNBS-induced colitis model, A 3 AR agonist 10, at a relatively high dose (3 mg/kg), reduced weight loss, diarrhoea, occult blood, and mucosal inflammation [38] . However, the results in other studies with A 3 AR agonists were variable [3] . The role of the A 3 AR in inflammatory diseases was recently reviewed [39] .
Crohn's disease (CD)
The inflammasome is a multiprotein complex belonging to the innate immune system and activation of P2X7R results in secretion of inflammatory cytokines. A significant difference in expression of the inflammasome in CD patients was observed, with increased expression of interleukin-1b and activation of the P2X7R [40] . There is overexpression of P2X7R in the inflamed mucosa in CD, suggesting that P2X7R may be a novel target for CD [41] .
A randomized placebo-controlled, double blind, Phase IIa Study in 34 patients (24 AZD9056 and 10 placebo) was done to assess the safety and efficacy of an oral P2X7R antagonist, AZD9056 32 in adult patients with moderately to severely active CD [28 ] . This is the first study done to evaluate a purinergic drug in IBD. AZD9056 was well tolerated and there were no serious adverse events reported. AZD9056 caused a significant improvement in CDAI (the primary end point) versus placebo. A decrease in disease activity was observed for pain and general well being, two subcomponents of CDAI. The improvement in abdominal pain was significantly greater for AZD9056 than placebo. The remission and response rates (secondary end point) and the reduction in inflammatory biomarkers (including serum C-reactive protein and fecal calprotectin) were not different versus placebo. Therefore, assuming AZD9056 is an effective P2X7R antagonist in humans, this study does not provide any evidence for a therapeutic effect for AZD9056 as an anti-inflammatory drug in CD, despite the evidence in animal models. Overall, the study demonstrates that AZD9056 has the potential to improve symptoms as in particular abdominal pain, in patients with moderate to severe CD. Clearly, further studies are needed to determine whether AZD9056 (or other P2X7R antagonists) is an effective therapy for chronic abdominal pain and whether it has anti-inflammatory potential. The former possibility is supported by accumulating evidence for a role of P2X7R in nociception [42, 10] . Furthermore, a vesicular ATP release inhibitor is an effective treatment of neuropathic and inflammatory pain in mice [43] , presumably by acting at P2X7R or other P2XR.
Pentostatin has shown benefit in colitis patients in which IL10 is absent [44] . The plasma levels of the two ADA isozymes are considered a biomarker of inflammation in CD [45] .
Purinergic signalling pathways in enteric glia and neurons as a target for IBD and motility disorders
Emerging evidence suggests that reactive enteric glia or alterations in glia induced by inflammation, infection or surgical intestinal manipulation/trauma may contribute to disturbed motility in intestinal diseases including postoperative ileus, GI symptoms in Parkinson's Disease (i.e. constipation), idiopathic severe slow transit constipation, diverticular disease, IBD, infectious colitis, and necrotizing enterocolitis. Common features in these diseases that suggest a role for glia in pathogenesis are alterations in the expression of glial proteins (GFAP, GDNF, s100B), a sign of glial activation or reductions in numbers of glia or size of the glial network. In an IBS model, glia are involved in a stress-induced colonic hypercontractility. In a gut surgical manipulation model of postoperative ileus, enteric glia are involved in abnormal motility (slow transit) (reviewed by [3] ).
Enteric glial cells contribute to intestinal disease via neuronal P2X7R. ATP release during inflammation causes neuronal death and gut motor dysfunction by activating neuronal P2X7R to trigger ATP release and activation of surrounding enteric glia [46] . Glia also modulate enteric neuron death in colitis through purinergicconnexin-43 pathways driven by NO production from iNOS in glia. Data suggest that the glial responses to ATP contribute to neurotoxic effects and motility disorders. Enteric glial activation is an important mechanism in the development of enteric neuropathy and glial purinergic signalling pathways represent a potential new target for the development of more effective treatments for functional bowel disorders [47 ] .
Much of our knowledge of purinergic signalling in the enteric nervous system (ENS) relies on data from animals (see Figure 1) . A recent study in isolated human enteric glial cells in culture obtained from non-diseased colon surgical specimens obtained from colectomy patients for polyp removal have revealed that inflammation (i.e. bacterial lipopolysaccharide) can induce a reactive glial phenotype associated with upregulation of cytokines, chemokines and alterations in purinergic gene expression, including P2X receptors, P2Y receptors and enzymes involved in purine metabolism [48 ] . In reactive glia induced by chronic stimulation with lipopolysaccharide, there is an increase in ATP release, and there is disruption of Ca 2+ waves, responses to ATP and mechanically evoked glial Ca 2+ responses. All together, data indicate that inflammation has a profound influence on purinergic signalling pathways in glia and Ca 2+ waves, which are required for normal motility and intestinal transit. Such effects are expected to cause disturbances in motility in the human intestinal tract.
Ca
2+ imaging was also used to study the purinergic receptor neuropharmacology in the human submucous plexus of surgical specimens. The study revealed that stimulatory P2X1R, P2X2R and P2X3R, and inhibitory P2YR and A 3 AR are involved in neurotransmission. Several types of neurons were identified based on their P2X receptor subtype expression [49 ] . P2X1R is highly expressed in human submucous neurons, and this could represent a potential species difference from rodents. Purines regulate neurotransmission at several synapses in the human enteric nervous system. One or more neural receptors identified are novel targets in GI diseases and enteric neuropathies.
Motility disorders
A review, focussed on the physiological mechanisms responsible for nerve-mediated purinergic relaxation, provides a functional basis for clinical and pharmacological studies on defective GI motility [50] .
The phytoalkaloid berberine is traditionally used to treat GI motility disorders, but it is not used as a treatment strategy in the USA. In a recent study, berberine was shown to decrease the amplitude and frequency of pacemaker potentials via ATP sensitive K + channels [51] . The purinergic fast inhibitory junction potential may be impaired in Hirschsprung's disease [52] .
A side effect of morphine pain treatment is persistent constipation and inflammation. Prolonged treatment with morphine causes a 'leaky gut' that predisposes to colonic inflammation. Connexin-purinergic signalling in enteric glia likely mediates the opioid induced constipation (OIC) and inflammation caused by long-term treatment with morphine [53 ] . The mouse model of opioidinduced constipation is associated with colonic inflammation and other features that could be markedly different from OIC in humans. For instance, it is evident that systemic inflammation occurs with chronic opioid use in man [54] but whether the gut is the origin remains unclear. It is also not yet known whether glial cells are activated by OIC in man. Targeting the connexin-purinergic pathway is a potential therapeutic target.
P2Y 1 R and Ca
2+ activated small-conductance K + (SK) channels are key components of inhibitory neurotransmission in the colon. An endogenous vasoconstrictor, adenosinyl uridinyl tetraphosphate (Up4A), activates P2Y 1 R and SK channels in human and mouse colon. Up4A is a novel mediator of purinergic signalling in human gut and in enteric inhibitory motor neurotransmission [55 ] , and is another mediator for consideration in gastrointestinal motility disorders.
Irritable bowel syndrome (IBS)
Diarrhoea-predominant IBS is characterised by abdominal pain and increased expression of P2Y 1 R and P2Y 2 R in the rectosigmoid mucosa of IBS patients [56] . P2Y 2 R expression may be correlated with abdominal pain. Visceral hypersensitivity is often seen in IBS. It has been suggested that P2X7R of rat dorsal root ganglia may play a role in the transmission of the nociceptive signal [57] . Emerging evidence suggests that electroacupuncture may downregulate the expression of the P2X3R and ease the sensitivity to IBS visceral pain [58] . It may be worth investigating AZD9056 32 in IBS and in related functional gastrointestinal disorders, since the P2X7R antagonist was shown to have some efficacy against chronic abdominal pain in CD [28 ] .
Gut pain
ATP release from mucosal epithelial cells, to activate P2X3R expressed on nociceptive primary afferent sensory nerve endings in the submucosa, was proposed to relay messages via the spinal cord to the conscious pain centres in the brain [59] . P2X3R antagonists and anti-P2X3R antibodies are being explored as therapeutic agents against colic and colitis pain [32, 60] .
Gastroesophageal reflux disease
Roles for adenosine, ATP and UTP in the pathogenesis of gastroesophageal reflux disease symptoms have been considered [61] . Purinergic receptors have been demonstrated in various species, including humans, and there is recent evidence to implicate a role for P2Y 2 and A 2A Rs in esophageal hypersensitivity.
Clinical studies have shown that adenosine contributes to esophageal mechanical hypersensitivity and non-cardiac chest pain originating in the esophagus [62] . Stimulation of A 2A AR induces mechanical sensitization of esophageal vagal nodose C fibers by a mechanism involving TRPA1. This may contribute to the effects of adenosine on hypersensitivity [63] .
Immune-mediated injury and IL-8 secretion has been proposed to play a role in the pathogenesis of gastroesophageal reflux disease (GERD). A recent study showed that ATP-induced activation of P2Y 2 R and IL-8 release maybe implicated in the pathogenesis of refractory GERD [35, 36] .
Gut cancer
High expression of the ecto-nucleotidase CD39 occurs in malignant epithelial cells of human rectal adenocarcinoma [64] . P2X7R activation mediated inflammatory responses and suppressed colitis-associated cancer development. Inactivation of the purinergic P2X7R dampens inflammation in a colitis model, but increases tumor incidence in a mouse colitis-associated cancer model [65 ] . Therefore, the use of P2X7R antagonists to treat IBD should be approached with some caution.
The protein kinase inhibitor H89 acts as an ATP mimetic, synergizing with a nitric oxide donor to trigger apoptosis in aggressive colonic cancer cells [66] .
Reviews focus on the pathophysiological roles of [70] P2YR in inflammation and cancer [29, 67] Gut infection Aged mice are less able to deal with inflammation from Candida albicans infection due to lower gut density of A 2A AR, which is an inflammation stop signal [68] .
Purinergic receptors have been proposed to be key mediators of human immunodeficiency virus type 1 (HIV-1) infection and inflammation [69] . Chronic HIV-1 infection leads to a decrease in the integrity of the mucosal epithelial barrier, bacterial translocation and high bacterial lipopolysaccharide levels in HIV-infected individuals. A better understanding of these pathways will provide further insight into disease pathogenesis and may enable more targeted therapies for HIV-infected patients.
Conclusions
Antagonists of P2XRs, and P2X7R and P2X3R, in particular, are potential therapeutic targets for treating IBD, IBS and motility disorders. Other targets include A 2A AR agonists, A 2B AR modulators, A 3 AR agonists and P2Y 2 R antagonists. Furthermore, modulation of the levels of endogenous purinoceptor agonists indirectly through enzymes and transporters can provide benefit in gastrointestinal disorders. MicroRNAs can also tune the levels of purinergic mediator proteins. Medicinal chemistry is facilitating the development of new purinergic agonists and antagonists with higher selectivity, potency, and a more favourable pharmacokinetic and safety profile for future clinical trials. Overall, pre-clinical studies provide compelling evidence for the potential therapeutic use of purinergic drugs for GI diseases and disorders [10] . Purinergic drugs have a favourable risk-benefit profile and carefully designed clinical trials to test feasibility, safety and efficacy in GI disorders should be encouraged. 
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